The company says this latest integration makes Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Compatibility in the U.S. comes about eight months after the company integrated Omnipod 5 with Libre 2 Plus in Europe.
Omnipod 5 already linked with Dexcom CGM, with the companies connecting their latest-generation offerings earlier this year. Abbott has launched a handful of FreeStyle Libre integrations this year alone. It paired Libre 2 Plus with the Tandem Diabetes Care t:slim X2 system in January. Then, it paired the next-generation Libre 3 Plus with Beta Bionics’ iLet system last month.
Insulet’s Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January 2022. It features SmartAdjust technology that predicts where glucose will be 60 minutes into the future every five minutes. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
Abbott modified its original FreeStyle Libre 2 for the purpose of integration with automated insulin delivery systems. It labeled it the first and only CGM in the U.S. worn for 15 days for adults and children. The FDA cleared the updated Abbott CGM for use with automated insulin delivery in March 2023.
“We are excited to announce that Omnipod 5, the only AID system indicated for both type 1 and type 2 diabetes, is now integrated with Abbott’s FreeStyle Libre 2 Plus sensor in the U.S. This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod therapy using their preferred CGM sensor,” said Eric Benjamin, Insulet EVP and chief product and customer experience officer. “As we work to reach more people with our innovative, tubeless Omnipod 5 AID system, today’s announcement represents yet another significant step forward for our company and our customers.”
